A new study led by physician-researchers at Beth Israel Deaconess Medical Center (BIDMC) reports that the antihypertensive drug amlodipine lowered long-term gout risk compared to two other drugs commonly prescribed to lower blood pressure. The findings are published in the Journal of Hypertension.
“Our study is clinically relevant as the prevalence of gout has been rising in the United States and the number of Americans meeting newly-revised diagnostic thresholds for hypertension has doubled,” said corresponding author Stephen Juraschek, MD, PhD, Assistant Professor of Medicine at BIDMC. “Our study demonstrated that amlodipine was associated with a lower risk of gout compared with chlorthalidone or lisinopril, which has never been reported prior to this study.”
Juraschek and colleagues conducted a secondary analysis of the data generated by the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). This clinical trial evaluated the effect of common blood pressure drugs on cardiovascular outcomes in more than 20,000 participants treated at 623 medical centers in North America between 1994 and 2002.
“Further research is needed to confirm these findings,” said Juraschek. “Other health outcomes, such as heart failure, should also be considered with choosing a blood pressure drug.”
In addition to Juraschek, authors included Robert H. Shmerling, MD, Jennifer L. Beach, MD, and Kenneth Mukamal, MD, MPH, MA, all of BIDMC; Kara M. Simpson, PhD, and Barry R. Davis, MD, PhD, of the Health Science Center at Houston at the University of Texas.
This work was supported by a grant from the National Institutes of Health/National Heart, Lung and Blood Institute (K23HL135273). The authors have no conflicts of interest to report.
About Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding.
BIDMC is in the community with Beth Israel Deaconess Hospital-Milton, Beth Israel Deaconess Hospital-Needham, Beth Israel Deaconess Hospital-Plymouth, Anna Jaques Hospital, Cambridge Health Alliance, Lawrence General Hospital, Signature Healthcare, Beth Israel Deaconess HealthCare, Community Care Alliance and Atrius Health. BIDMC is also clinically affiliated with the Joslin Diabetes Center and Hebrew Rehabilitation Center and is a research partner of Dana-Farber/Harvard Cancer Center and the Jackson Laboratory. BIDMC is the official hospital of the Boston Red Sox. For more information, visit www.bidmc.org.
BIDMC is part of Beth Israel Lahey Health, a new health care system that brings together academic medical centers and teaching hospitals, community and specialty hospitals, more than 4,000 physicians and 35,000 employees in a shared mission to expand access to great care and advance the science and practice of medicine through groundbreaking research and education.
Original post https://alertarticles.info